Migtera® in the Treatment of Migraines
Main Article Content
Abstract
The evidence base of the use antimigrenous drug of Migtera® (a.i. zolmitriptan) in the management of patients with migraine attacks, evaluation of its effectiveness in comparison with the used antimigrenous drug Rapimig (a.i. zolmitriptan) is considered. The results of studies of the treatment of these patients using antimigrenous drug Migtera® showed its equivalent efficacy and tolerability compared to patients taking basic therapy with antimigrenous drug Rapimig.
Article Details
References
Амелин А.В. Фармакотерапия приступа мигрени. //Справочник поликлинического врача.–2007–№9–С.3–6
Данилов А. Б., Современные подходы к лечению мигрени., LVRACH.RU, 2008-10- 5614756.
Кадыков А.С., Шахпаронова Н.В. Применение золмитриптана при лечении мигрени. РМЖ. 2007;24:1757.
Калашникова Л.А. Зомиг – новый селективный агонист серотониновых рецепторов в лечении приступа мигрени. //Неврологический журнал–1999–Т.4, №4–С.37–40
Осипова В.В. Принципы эффективного применения триптанов при купировании приступа мигрени. Медицинский совет, 2013, 4: 33-35.;
Табеева Г.Р. Принципы лечения мигрени. РМЖ, 2007, 10.
Табеева Г.Р., Яхно Н.Н. Мигрень. – М.: ГЭОТАР-Медиа, 2011. – 624 с.
Филатова Е.Г. READY – первое российское мультицентровое исследование эффективности препарата Релпакс (элетриптан) при лечении приступов мигрени. Лечение нервных нервных болезней, 2006, 2(19).
Alstadhaug K.B., Salvesen R., Bekkelund S.I. (2005) Seasonal variation in migraine. Cephalal-gia 25(10):811–816
Ashina M. (2020) Migraine. N. Engl. J. Med 383(19):1866-1876
Diamond M., Hettiarachchi J., Hilliard B. et al. Effectiveness of eletriptan in acute migraine: primary care for Exedrin nonresponders. Head-ache, 2004, 44: 209-216
Dodick D.W. Migraine (2018) Lancet 391(10127):1315–1330
Evers S, A´ fra J, Frese A et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol, 2009, 16: 968–981.
Goadsby P.B, Lipton R.B, Ferrari MD. Migraine: current understanding and management. N Eng J Med, 2002, 346: 257-270
https://evidence-neurology.ru/medical-calculators/headache/midas/
Lipton R.B., Buse D.C., Hall C.B., Tennen H., DeFreitas T.A., Borkowski T.M. et al (2014) Re-duction in perceived stress as a migrain. Neurol-ogy 82(16):1395–1401
Lipton R.B., Stewart W.F. Acute migraine thera-py: do doctors understand what patients with migraine want from therapy? Headache, 1999, 39: 30-48.
MacGregor E.A., Brandes J., Eikermann A. Mi-graine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation sur-vey. Headache, 2003, 43(1): 19-26.
Rasmussen B.K., Jensen R., Schroll M., Olesen J. Epidemiology of headache in a general popula-tion—a prevalence study. J Clin Epidemi-ol 1991; 44:1147–57.
Torelli P., Cologno D., Manzoni G.C. (1999) Weekend headache: A possible role of work and life-style. Headache 39(6):398–408
Tommaso M., Delussi M. Circadian rhythms of migraine attacks in episodic and chronic pa-tients: A cross sectional study in a headache cen-ter population. BMC Neurol (2018) 18(1):1–10.
Ferrari M.D., Roon K.I., Lipton R.B. et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 2001, 358: 1668-1675;